Five things for pharma marketers to know: Thursday, February 9, 2017

Five things for pharma marketers to know: Thursday, February 9, 2017

Court to allow Sanofi and Regeneron to market Praluent during appeal; Xarelto is effective in treating artery disease; VP advocates for right-to-try laws

Allergan to boost investment in DTC for Kybella

Allergan to boost investment in DTC for Kybella

Allergan said it would increase its investment in DTC after reporting slowing sales for its double-chin injection.

GSK prepares for Advair competition

GSK prepares for Advair competition

If generic versions by Mylan, Hikma, and Vectura are approved mid-year, GSK expects sales of Advair to be flat or decline.

Gilead to use dating sites, Tumblr, and Snapchat in Truvada strategy

Gilead to use dating sites, Tumblr, and Snapchat in Truvada strategy

The drugmaker is planning a commercial boost for its HIV-prevention drug.

Five things for pharma marketers to know: Wednesday, February 8, 2017

Five things for pharma marketers to know: Wednesday, February 8, 2017

Sanofi is not in a hurry to make a deal; Spicer says Trump supports Medicare drug price negotiations; HCV market is shrinking, Gilead execs say

Three kinds of drugs, like those that treat RA and diabetes, drive increase in spending

Three kinds of drugs, like those that treat RA and diabetes, drive increase in spending

Spending for inflammatory drugs like AbbVie's Humira and Amgen's Enbrel rose, while hepatitis C drugs showed decline.

Allergan campaign focuses on preventable blindness

Allergan campaign focuses on preventable blindness

The aim is not only to urge people to get regular eye exams, but also to maintain good health, as many other preventable diseases like diabetes can lead to vision loss.

Five things for pharma marketers to know: Tuesday, February 7, 2017

Five things for pharma marketers to know: Tuesday, February 7, 2017

Teva CEO steps down; Mylan to pay $96.5 million to settle pay-for-delay claims; Merck files Keytruda with the FDA for bladder cancer

Marketers take a new approach to lung-cancer campaigns, and why that matters

Marketers take a new approach to lung-cancer campaigns, and why that matters

Each of the approaches is valid and more ambitious than a great majority of the campaigns that preceded them.

Lawmakers reintroduce bill to include PAs and NPs in Open Payments reporting

Lawmakers reintroduce bill to include PAs and NPs in Open Payments reporting

The bill, if enacted, would publicly share information about industry payments to physician assistants and nurse practitioners.

Five things for pharma marketers to know: Monday, February 6, 2017

Five things for pharma marketers to know: Monday, February 6, 2017

Novo Nordisk CEO describes 'volatile' pricing environment; Lilly to cut 200 research and development jobs; pharma opts out of Super Bowl this year

How can drugmakers tell better stories? Try Instagram

How can drugmakers tell better stories? Try Instagram

The Kim Kardashian debacle aside, what makes the platform so potentially valuable to pharma and healthcare marketers is its visual story-telling capability.

10 ways healthcare companies are testing Instagram

10 ways healthcare companies are testing Instagram

Pharmaceutical and healthcare companies use a mix of corporate and brand accounts on Instagram, and some are turning to celebrity influencers.

Five things for pharma marketers to know: Friday, February 3, 2017

Five things for pharma marketers to know: Friday, February 3, 2017

Trial finds that Repatha reduces risk of heart attack and stroke; California measure would ban drug coupons in some cases; Takeda to limit price increases

Sales of Keytruda miss analysts' mark

Sales of Keytruda miss analysts' mark

Thirty-percent of Keytruda's U.S. sales came from its lung-cancer indication.

Merck campaign shows impact of shingles

Merck campaign shows impact of shingles

To drive the point home, the ads even feature an image of an actual case of shingles. The blistering red rash appears on-screen for several seconds.

Five things for pharma marketers to know: Thursday, February 2, 2017

Five things for pharma marketers to know: Thursday, February 2, 2017

Biogen completes hemophilia spinoff; old drug being tested as a prostate cancer treatment; Merck reports Q4 decline in revenue

BreathResearch's Nirinjan Yee on being a female entrepreneur

BreathResearch's Nirinjan Yee on being a female entrepreneur

A bout with Lyme disease led Yee to found a company that helps patients measure and track their breathing patterns.

WPP to merge Ogilvy CommonHealth, ghg, Sudler, and CMI into new company

WPP to merge Ogilvy CommonHealth, ghg, Sudler, and CMI into new company

A WPP insider has been tapped as CEO of WPP Health & Wellness, and Ogilvy CommonHealth chairman/CEO Matt Giegerich is stepping down.

Five things for pharma marketers to know: Wednesday, February 1, 2017

Five things for pharma marketers to know: Wednesday, February 1, 2017

Trump wants to speed up drug approvals; Sanofi allergy drug gets OTC approval; Lilly ends final solanezumab trial

MM&M's top 5 stories in January 2017

MM&M's top 5 stories in January 2017

Merck and Aetna partner in value-based drug pricing; data scientists rising in the biopharma ranks; Japanese pharma leads digital health innovation

WPP wins Walgreens account, to create 'Team WBA'

WPP wins Walgreens account, to create 'Team WBA'

WPP will create "Team WBA," a bespoke team that would work on traditional and digital advertising, media, and PR.

The 2017 MM&M Awards is now open for entries

The 2017 MM&M Awards is now open for entries

The annual awards program has added three new categories.

Merck launches DTC campaign for Keytruda

Merck launches DTC campaign for Keytruda

The drugmaker previously launched an unbranded campaign about lung-cancer biomarkers.

Five things for pharma marketers to know: Tuesday, January 31, 2017

Five things for pharma marketers to know: Tuesday, January 31, 2017

Diabetes patients sue drugmakers over price increases; the FTC opens Mylan investigation; Fitbit to ramp up marketing

Five things for pharma marketers to know: Monday, January 30, 2017

Five things for pharma marketers to know: Monday, January 30, 2017

Merck details price increases for its drugs; Trump's call to freeze federal hiring may not affect the FDA; Sanofi to settle vaccines-pricing lawsuit

Infographic: What payers want from pharma

Infographic: What payers want from pharma

One pharmacy director would like to see a lot more comparative data about new therapies.

Merck and Aetna pair population health with risk-sharing, in two deals

Merck and Aetna pair population health with risk-sharing, in two deals

But have pharma and payers learned enough from earlier pilots to make modern risk-sharing deals work?

Five things for pharma marketers to know: Friday January 27, 2017

Five things for pharma marketers to know: Friday January 27, 2017

BMS cuts forecast after Opdivo setbacks; diabetes death rate rises; McKesson acquires prior authorization startup

Infographic: How Trump will affect healthcare marketing budgets

Infographic: How Trump will affect healthcare marketing budgets

A new survey found that 34% of healthcare and pharma marketers say that the election of President Trump will not affect their marketing budgets.

Survey: 26% of brand execs say Trump will affect 2017 marketing budgets

Survey: 26% of brand execs say Trump will affect 2017 marketing budgets

A Haymarket Media survey of more than 700 client-side marcomms execs in the US reveals the shift in power will not significantly affect budgets.

Five things for pharma marketers to know: Thursday, January 26, 2017

Five things for pharma marketers to know: Thursday, January 26, 2017

J&J to buy Actelion for $30 billion; Pfizer fights advertising ban related to Advil; almost half of women with breast cancer report severe side effects

Continuum and Lyft to offer free rides to clinical-trial patients

Continuum and Lyft to offer free rides to clinical-trial patients

Transportation barriers can limit patient involvement in clinical trials.

Patients are increasingly asking docs about drugs in DTC ads: poll

Patients are increasingly asking docs about drugs in DTC ads: poll

Docs said patients asked about drugs from DTC ads six times in a typical week, compared to just twice a week five years ago.

Five things for pharma marketers to know: Wednesday, January 25, 2017

Five things for pharma marketers to know: Wednesday, January 25, 2017

Novartis forecasts slower growth in 2017; Actelion reports trial failure for PAH drug; HHS nominee Tom Price denies conflict of interest claims

Mike Lazur, 2017 MAHF inductee, on his medical advertising destiny

Mike Lazur, 2017 MAHF inductee, on his medical advertising destiny

He played a leading role during Torre Lazur's glory era as "the launch agency." Now he is being inducted into the Medical Advertising Hall of Fame.

Ryan Abbate, 2017 MAHF inductee, sets the record straight

Ryan Abbate, 2017 MAHF inductee, sets the record straight

The founder of Pacific Communications shares the details of his career as he is inducted into the Medical Advertising Hall of Fame.

Five things for pharma marketers to know: Tuesday, January 24, 2017

Five things for pharma marketers to know: Tuesday, January 24, 2017

Endo settles pay-for-delay charges; Trump signs order withdrawing U.S. from TPP; administration considers Patrick Soon-Shiong for healthcare role

FDA guidance seeks to clarify pharma comms with payers

FDA guidance seeks to clarify pharma comms with payers

But it may also increase the reporting burden for drugmakers.

Five things for pharma marketers to know: Monday, January 23, 2017

Five things for pharma marketers to know: Monday, January 23, 2017

BMS and Ono settle Keytruda patent suit; PhRMA plans to release new campaign; Trump moves forward with plans to scale back the ACA

Lexicon developing type 1 diabetes treatment with Sanofi

Lexicon developing type 1 diabetes treatment with Sanofi

Type 2 diabetes has been hogging health headlines lately — and for good reason. But the incidence of type 1 diabetes is also on the rise.

Top 25 metabolic brands, by sales, 2015-2016

Top 25 metabolic brands, by sales, 2015-2016

Sanofi's Lantus is the top-selling product with its Lantus franchise. Merck's Januvia and Novo Nordisk's Victoza round out the top 3.

When it comes to diabetes, will marketers break with tradition?

When it comes to diabetes, will marketers break with tradition?

That may take a "focus on brand building that goes beyond 'ask your doctor if this drug is right for you.'"

6 personalization practices from Walgreens' Balance Rewards program

6 personalization practices from Walgreens' Balance Rewards program

How the retail pharmacy chain uses customer data to make its marketing messages relevant.

Healthcare communicators track Obamacare repeal debate

Healthcare communicators track Obamacare repeal debate

Many healthcare comms leaders are paying close attention to the debate between "access" to healthcare versus making it a requirement, experts say.

Five things for pharma marketers to know: Friday, January 20, 2017

Five things for pharma marketers to know: Friday, January 20, 2017

Pharma among top sponsors of Trump inauguration parties; AstraZeneca exec to replace GSK president of global pharmaceuticals; EpiPen rival to relaunch

In draft guidance, the FDA defines appropriate off-label comms as being 'consistent' with the label

In draft guidance, the FDA defines appropriate off-label comms as being 'consistent' with the label

The regulator is providing examples of appropriate off-label communications.

Five things for pharma marketers to know: Thursday, January 19, 2017

Five things for pharma marketers to know: Thursday, January 19, 2017

The FDA releases three documents; PBM rebates eating into drugmaker revenue: PhRMA; most oncologists on Twitter receive money from pharma

Wunderman Health taps former Merkle exec as SVP of strategy and analytics

Wunderman Health taps former Merkle exec as SVP of strategy and analytics

Deborah Furey will lead the agency's pilot of a new personalized marketing offering.

MM&M opens nominations for Hall of Femme

MM&M opens nominations for Hall of Femme

MM&M last year named its inaugural class of 16 Femmes and 20 Women to Watch. Who should be considered for this year's list of breakthough women?

Five things for pharma marketers to know: Wednesday, January 18, 2017

Five things for pharma marketers to know: Wednesday, January 18, 2017

Rep. Price to answer questions at confirmation hearing; 22 drugmakers invest in fighting disease in poor countries; FDA approves generic of Jazz's Xyrem

Industry hires and promotions: January 2017

Industry hires and promotions: January 2017

Endo hires new head of U.S. branded pharma, and three other people moves for you to know about.

The FDA targeted DTC, video, unapproved drug promotion in 2016

The FDA targeted DTC, video, unapproved drug promotion in 2016

The agency issued 11 enforcement letters last year.

Five things for pharma marketers to know: Tuesday, January 17, 2017

Five things for pharma marketers to know: Tuesday, January 17, 2017

Biogen to pay $1.25 billion for patents to MS drugs; Supreme Court to hear Novartis case over Zarxio delay; Merck KGaA inks big-data deal

Trump administration raises questions for rare-disease drugmakers

Trump administration raises questions for rare-disease drugmakers

Nobody knows what the future holds for the Affordable Care Act under the Trump administration and an emboldened Republican Congress.

If CSL Limited CEO Paul Perreault sneezes, Australia gets a cold

If CSL Limited CEO Paul Perreault sneezes, Australia gets a cold

"In Australia, we are the healthcare industry," he says.

Five things for pharma marketers to know: Friday, January 13, 2017

Five things for pharma marketers to know: Friday, January 13, 2017

CVS to sell generic EpiPen; FDA finalizes biosimilar naming rules; Pfizer wants to make a deal

GCI Health plants its flag in Philadelphia

GCI Health plants its flag in Philadelphia

The firm is sharing space in the City of Brotherly Love with healthcare media shop CMI.

Day 3 at JP Morgan: The move toward big data requires drugmakers to ask questions

Day 3 at JP Morgan: The move toward big data requires drugmakers to ask questions

There are dozens of players, including leaders like IBM Watson Health and Verily as well as smaller concerns, lining up to sell pharma access to some sort of data solution.

Five things for pharma marketers to know: Thursday, January 12, 2017

Five things for pharma marketers to know: Thursday, January 12, 2017

Trump says pharma is "getting away with murder"; Senate majority votes to repeal ACA; IBM Watson Health and FDA to study blockchain technology

Merck's Keytruda combo could edge out the competition

Merck's Keytruda combo could edge out the competition

Merck said the FDA accepted its submission of a Keytruda/chemotherapy combo drug and granted it Priority Review.

Day 2 at JP Morgan: Change is coming, but which drugmakers will stay on top?

Day 2 at JP Morgan: Change is coming, but which drugmakers will stay on top?

J&J's CEO may be right. Customers of all kinds are demanding change.

Five things for pharma marketers to know: Wednesday, January 11, 2017

Five things for pharma marketers to know: Wednesday, January 11, 2017

The FDA accepts Keytruda combo for review; Valeant offloads Dendreon and skincare brands; pharmacies feeling the squeeze from Express Scripts

Tonic Life promotes Stephanie DeViteri to MD

Tonic Life promotes Stephanie DeViteri to MD

DeViteri started in the newly created role this month.

Physicians group urges metformin rather than new drugs

Physicians group urges metformin rather than new drugs

The American College of Physicians said the costs of some new diabetes drugs do not always mean added benefits for patients.

Infographic: Can pharma give doctors what they want?

Infographic: Can pharma give doctors what they want?

Physicians do not like EHRs. That much is clear. But the vast majority have to use electronic record systems on a daily basis. What can pharma do to better give doctors what they want?

Day 1 at JP Morgan: Pricing is top of mind for pharma CEOs

Day 1 at JP Morgan: Pricing is top of mind for pharma CEOs

The questions being asked about how drugs are priced are weighing heavily on pharma leaders, and they know the issue is not going away.

Five things for pharma marketers to know: Tuesday, January 10, 2017

Five things for pharma marketers to know: Tuesday, January 10, 2017

Illumina and IBM enter DNA sequencing partnership; J&J to outline price increases in new report; Egalet's opioid Arymo ER gets FDA approval

Top 25 cardiovascular brands, 2015-2016

Top 25 cardiovascular brands, 2015-2016

The top-selling heart drug is Merck's Zetia, which is expected to bring in about $1.68 billion in sales in 2016.

For statin-intolerant patients, what's next?

For statin-intolerant patients, what's next?

Despite their blockbuster status and distinction as the world's most widely prescribed class of drugs, statins may not be the best option for all patients with elevated low density lipoprotein (LDL) cholesterol levels.

When it comes to PCSK9s, payers resisted — and sales flopped

When it comes to PCSK9s, payers resisted — and sales flopped

The first two PCSK9s landed with a thud. What does their disappointing launch say about the need for marketers of CV drugs to get their pricing houses in order?

Ex-Guidemark CEO Matt Brown hangs out new shingle, Brand Mettle

Ex-Guidemark CEO Matt Brown hangs out new shingle, Brand Mettle

The new agency will focus on marketing goods and services to people 50 years of age and older.

MMC's Diana Littman on waiting for a decision after a pitch

MMC's Diana Littman on waiting for a decision after a pitch

She says her experience in consumer brands helps her push healthcare clients to be more creative.

Five things for pharma marketers to know: Monday, January 9, 2017

Five things for pharma marketers to know: Monday, January 9, 2017

Takeda to acquire Ariad for $4.6 billion, Merck pairs with Incyte for Keytruda combo drug collaboration; Sanofi announces autoimmune research deal

Japanese drugmakers lead the way in digital innovation

Japanese drugmakers lead the way in digital innovation

Otsuka, Astellas, Takeda, and Daiichi Sankyo share a degree of adventurousness and forward-mindedness in the digital realm.

Shark Tank's Herjavec shares his tips for innovation competitions

Shark Tank's Herjavec shares his tips for innovation competitions

When his mother suffered from ovarian cancer a decade ago, Robert Herjavec found himself frustrated by the quality of care she received.

Five things for pharma marketers to know: Friday, January 6, 2017

Five things for pharma marketers to know: Friday, January 6, 2017

Judge halts Praluent sales; clinical-trial data for Diclegis in question; cancer drugs to make up larger portion of total drug spending

The FDA to study whether people can recognize misleading drug ads

The FDA to study whether people can recognize misleading drug ads

The agency has faced questions about how it regulates off-label communications.

Five things for pharma marketers to know: Thursday, January 5, 2017

Five things for pharma marketers to know: Thursday, January 5, 2017

Orexigen launches new campaign for weight-loss drug Contrave; Arena sells Belviq to Eisai; Alexion reportedly pushed for 'pull-in' sales

QuintilesIMS taps Staub as head of R&D solutions

QuintilesIMS taps Staub as head of R&D solutions

The merger of Quintiles and IMS Health closed in October.

Five things for pharma marketers to know: Wednesday, January 4, 2017

Five things for pharma marketers to know: Wednesday, January 4, 2017

Sanofi, Regeneron denied bid to overturn Amgen win in patent case; Abbott to close St. Jude deal; Gilead hires SVP of hematology and oncology

The FDA in 2016: By the numbers

The FDA in 2016: By the numbers

With 2016 in the rearview, here are four stats detailing how the FDA fared last year in enforcing regulations and approving new drugs.

How different generations form online "tribes"

How different generations form online "tribes"

Facebook and Instagram are the primary location for brands to engage with online tribes, while Raptr and PlayFire are a hit with boomers.

Five things for pharma marketers to know: Tuesday, January 3, 2017

Five things for pharma marketers to know: Tuesday, January 3, 2017

The FDA approves 22 new drugs in 2016; the Philippines orders Sanofi to stop Dengvaxia ads; new spinal muscular atrophy drug to cost $375,000

Big data expert Hilary Mason on 3 ways to create a data-driven culture

Big data expert Hilary Mason on 3 ways to create a data-driven culture

The first step is to seek leadership support, she says.

Why healthbots may eat search ads and mobile apps

Why healthbots may eat search ads and mobile apps

The internet strongly agrees there's an artificial intelligence revolution going on, and it's come to pharma marketing.

Pharma adopts data-science culture in move toward AI

Pharma adopts data-science culture in move toward AI

Data scientists are a new kind of insight and analytics professional showing up in the biopharma ranks.

Five things for pharma marketers to know: Thursday, December 29, 2016

Five things for pharma marketers to know: Thursday, December 29, 2016

Gilead forms network to encourage access to hep.-C drugs; Dentsu CEO to resign following the suicide of a staffer; BI to divest animal-health products

MM&M's top health technology stories of 2016

MM&M's top health technology stories of 2016

We at MM&M found out just how much pharma marketers love a list. Here, read through the year's most-read technology stories.

Five things for pharma marketers to know: Wednesday, December 28, 2016

Five things for pharma marketers to know: Wednesday, December 28, 2016

Sanofi sues Novo over Tresiba marketing; the FDA issues two more untitled letters; U.S. health spending rose substantially from 1996 to 2013

MM&M's top stories of 2016

MM&M's top stories of 2016

Find out what stories generated the most interest among our readers.

Five things for pharma marketers to know: Tuesday, December 27, 2016

Five things for pharma marketers to know: Tuesday, December 27, 2016

Allergan's board endorses its social contract with patients; drugmakers that market painkillers are hiring DEA officials; the FDA approves new Biogen drug

Luxottica looks to 360 video to highlight childhood vision

Luxottica looks to 360 video to highlight childhood vision

When the vision company needed to demonstrate to parents the plight of children struggling to see, it turned to Olson 1to1 and a 360 video to tell the story.

Five things for pharma marketers to know: Thursday, December 22, 2016

Five things for pharma marketers to know: Thursday, December 22, 2016

Senate report said certain drugmakers act like hedge funds; ViiV to develop HIV prevention drug; lawmakers to replace ACA with "universal access"

Read the complete December 2016 digital edition

Read the complete December 2016 digital edition

Here you'll find everything you need to know from MM&M's December 2016 issue, including our policy outlook for pharma in a Republican-led White House and Congress and the exclusive pipeline report.

Five things for pharma marketers to know: Wednesday, December 21, 2016

Five things for pharma marketers to know: Wednesday, December 21, 2016

GSK's two-drug combo for HIV has positive Phase-III results; the FDA approves glucose system that doesn't use finger pricking; Rite Aid to sell stores

The FDA issues two more enforcement letters this week

The agency has sent nine untitled and warning letters so far this year.

CME providers use Facebook Live to educate doctors

CME providers use Facebook Live to educate doctors

A recent CME course using Facebook Live generated 34,000 views and 600 comments.

Five things for pharma marketers to know: Tuesday, December 20, 2016

Five things for pharma marketers to know: Tuesday, December 20, 2016

Biogen names new CEO; the FDA issues two warning letters; Allergan to acquire aesthetics firm

Drugmakers formalize patient roles as they work to define patient centricity

Drugmakers formalize patient roles as they work to define patient centricity

For years pharma has said it needs to be more focused on patients, has it delivered?

OPINION

Newsletters